Posted by Michael Wonder on 18 Nov 2016
U.S. FDA grants fast track designation for the development of Eisai's BACE inhibitor E2609 for early Alzheimer's disease
18 November 2016 - Eisai announced today that the U.S. FDA has granted fast track designation for the development of the beta secretase cleaving enzyme (BACE) inhibitor E2609 which was discovered by Eisai and is being jointly developed by Eisai and Biogen Inc.
E2609 is currently being investigated in Phase III clinical studies for early Alzheimer's disease.
